The current financial score of Pacira Biosciences Inc is 8.94. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 192.40M, representing a year-over-year increase of 6.24%, while its net profit experienced a year-over-year increase of 196.00%.
The current valuation score of Pacira Biosciences Inc is 8.05. Its current P/E ratio is 289.02, which is 0.08% below the recent high of 289.25 and 230.63% above the recent low of -377.53.
The current earnings forecast score of Pacira Biosciences Inc is 6.00. The average price target is 34.44, with a high of 36.50 and a low of 25.00.
The current price momentum score of Pacira Biosciences Inc is 5.67. Currently, the stock price is trading between the resistance level at 40.52 and the support level at 28.41, making it suitable for range-bound swing trading.
The current institutional shareholding score of Pacira Biosciences Inc is 10.00. The latest institutional shareholding proportion is 122.53%, representing a quarter-over-quarter increase of 1.68%.
The current risk assessment score of Pacira Biosciences Inc is 5.06. The company's beta value is 0.30. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.